Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioSphincter for Severe Passive Fecal Incontinence
NCT05616208Phase 1Active, not recruiting
- Sponsor
- Cellf BIO
- Start
- Nov 2022
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BioSphincter in fecal incontinence (FI), sponsored by Cellf BIO. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 36 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
BioSphincter
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT05616208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616208.